Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>On July 18, 2024, Cocrystal Pharma, Inc. (COCP) reported favorable safety and tolerability results from the single-ascending dose (SAD) cohorts of the Phase 1 study of CDI-988, the company's pan-viral protease inhibitor that is being developed as a treatment of norovirus and coronavirus.</li><li>The single center, randomized, double blind Phase 1 trial is evaluating the safety, tolerability, and pharmacokinetics of CDI-988 compared to placebo in healthy adults in doses ranging from 100 mg to 600 mg.</li><li>The results showed that all participants completed the study with no discontinuations and there were no serious adverse events or severe treatment-emergent adverse events.</li></ul>

On July 18, 2024, Cocrystal Pharma, Inc. (COCP) reported favorable safety and tolerability results from the single-ascending dose (SAD) cohorts of the Phase 1 study of CDI-988, the company's pan-viral protease inhibitor that is being developed as a treatment of norovirus and coronavirus.The single center, randomized, double blind Phase 1 trial is evaluating the safety, tolerability, and pharmacokinetics of CDI-988 compared to placebo in healthy adults in doses ranging from 100 mg to 600 mg.The results showed that all participants completed the study with no discontinuations and there were no serious adverse events or severe treatment-emergent adverse events.

COCP: Phase 1 Single-Ascending Dose Cohort of CDI-988 Shows it is Safe and Well Tolerated 

<ul><li>On May 1, 2024, Cocrystal Pharma, Inc. (COCP) announced the completion of enrollment of 78 subjects in the randomized, double blind, placebo controlled Phase 2a human challenge trial of CC-42344.</li><li>Study subjects were infected with influenza A and then treated with CC-42344 or placebo.</li><li>We anticipate topline results in the second half of 2024.</li></ul>

On May 1, 2024, Cocrystal Pharma, Inc. (COCP) announced the completion of enrollment of 78 subjects in the randomized, double blind, placebo controlled Phase 2a human challenge trial of CC-42344.Study subjects were infected with influenza A and then treated with CC-42344 or placebo.We anticipate topline results in the second half of 2024.

COCP: Enrollment Complete in Phase 2a Human Challenge Trial of CC-42344 

United States

TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating safe and effective branded and generic prescription, and over-the-counter products targeted exclusively for women. The Company develops three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies.

Iterum Therapeutics Public Limited Company operates as a a clinical-stage pharmaceutical company. The Company develops and markets therapies to address unmet medical needs, as well as provides anti-infectives to treat multi-drug resistant pathogens. Iterum Therapeutics serves physicians and patients worldwide.

Kubota Pharmaceutical Holdings Co.,Ltd. operates as a holding company. The company, through its subsidiaries, specializes in identifying and developing therapeutics to treat the ophthalmic disorders. Kubota Pharmaceutical Holdings serves customers worldwide.

Agile Therapeutics, Inc. develops women's healthcare products. The Company provides contraceptive patch containing the active ingredients levonorgestrel and ethinyl estradiol, as well as progestin-only birth control patch. Agile Therapeutics discovers a pipeline of investigational contraceptive products in the United States.

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company develops, discovers, and commercializes aesthetics and dermatology based products for inflammatory skin diseases, tissue injury, and unwanted light-pigmented hair reduction. Sienna Biopharmaceuticals serves patients in the United States and Italy.

Tricida, Inc. operates as a bio-pharmaceutical company. The Company focuses on the discovery and clinical development of novel therapeutics to address renal, metabolic, and cardiovascular diseases. Tricida serves patients in the United States.

CNBX Pharmaceuticals Inc. operates as a pharmaceutical company. The Company develops cannabinoid-based antitumor drug candidate for the treatment of colorectal cancer based on novel and proprietary formulation. CNBX Pharmaceuticals serves patients in the United States.

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company develops next-generation synthetic cannabinoid therapeutics for transdermal delivery for patients with significant unmet medical needs. Zynerba Pharmaceuticals serves the healthcare sector and patients in the United States.

Assembly Biosciences Inc. is a biopharmaceutical company. The Company is focused in the field of infectious diseases such as the Hepatitis B virus (HBV) and clostridium difficile (CDAD). Assembly is developing two proprietary platforms: an HBV-cure platform focused on oral drugs with novel direct-acting mechanisms, and an orally-delivered microbiome therapeutics platform for treating CDAD.

Odonate Therapeutics, Inc. operates as a pharmaceutical company. The Company develops an oral chemotherapy drugs for the treatment of cancer. Odonate Therapeutics offers its services worldwide.

Bal Pharma Limited researches and develops bulk drugs and intermediates.

Indofarma Persero Tbk PT manufactures and trades drugs. The Company's products include generic, branded, licensed, and over the counter (OTC) drugs as well as traditional herbs, health food, cosmetics, and supplementary baby food. Through its subsidiaries, Indofarma also produces packaging materials, machinery and equipment, and infrastructure related to pharmaceutical industry.

Choa Pharmaceutical Company manufactures, wholesales, and retails pharmaceutical products including digestives, antibiotics, and nutrition and tonics in a drinkable double neck ampoule and solid dosage forms.

Shenzhen Neptunus Interlong Bio-technique Co.Ltd. engages in the R&D, production, and sales and distribution of biological pharmaceuticals. The Company specializes in gene engineering drugs and preventive biological products.

Shenzhen Neptunus Interlong Bio Tech Co (8329 HK)

Syntara Limited operates as a clinical stage drug development company. The Company develops therapeutic products for blood related cancers. Syntara serves customers in Australia.

Starpharma Holdings Limited is biotechnology company involved in the research, development and commercialization of dendrimer-based for pharmaceutical, life sciences and other applications. The Company's lead product in development is VivaGel, a microbicide gel for women, for the prevention and treatment of bacterial vaginosis adn a range of sexually transmitted diseases.

Guangdong Taiantang Pharmaceutical Co.,Ltd develops, manufactures and sells Chinese pharmaceuticals.  The Company's products include skin type ointments and pills, and cardiovascular drugs.

Guangdong Taiantang Pharmaceuticl (002433 CH)

Qinghai Gelatin Co., Ltd. manufactures and markets Chinese medicines and a series of gelatin products for pharmaceutical, food, photographic film, and industrial use.  The Company also produces hard capsules for pharmaceutical and cosmetic industries, as well as researches and produces biomedical products.

Invion Limited develops pharmaceutical products for the treatment of asthma and smoking cessation.  The Company also is involved in the treatment autoimmune and inflammatory diseases, such as rheumatoid arthritis.

KYUNG NAM PHARM CO., LTD. manufactures and research in the development of pharmaceutical ingredients. The Company provides human placenta ingredients to pharmaceutical manufacturers. It also provides vitamin and cosmetic products through its subsidiaries.

Cocrystal Pharma, Inc. operates as a biotechnology company. The Company focuses on developing novel antiviral therapeutics for hepatitis, influenza viruses, and noroviruses. Cocrystal Pharma serves patients in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cocrystal Pharma (COCP US)

COCP: Phase 1 Single-Ascending Dose Cohort of CDI-988 Shows it is Safe and Well Tolerated

On July 18, 2024, Cocrystal Pharma, Inc. (COCP) reported favorable safety and tolerability results from the single-ascending dose (SAD) cohorts of...

Zacks Small Cap Research

COCP: Enrollment Complete in Phase 2a Human Challenge Trial of CC-42344

On May 1, 2024, Cocrystal Pharma, Inc. (COCP) announced the completion of enrollment of 78 subjects in the randomized, double blind, placebo...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)